SanReno Therapeutics

Pharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Welcome to the Year of the Dragon! Entering 2024, there have already been multiple recent deals between Chinese innovative drug developers and multinationals, including Medilink and Roche Holding AG

Founded only one year ago with a leading asset licensed from Jiangsu Hengrui Medicine Co., Ltd. , Chinese bioventure Aiolos Bio is now being acquired by GSK plc in a major deal. Set up two years ag